Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Pharm Bull ; 41(2): 239-246, 2018.
Article in English | MEDLINE | ID: mdl-29386483

ABSTRACT

This present study aimed to determine the optimal oral insulin delivery conditions that would maximize the utility of cell-penetrating peptides (CPPs) by using a noncovalent strategy. We first compared the effectiveness of two potential CPPs, penetratin and its analog PenetraMax, as absorption enhancers for insulin. The combined effect was evaluated under in vivo oral administration conditions. Both D-forms of CPPs were highly effective for increasing the oral absorption of insulin, and D-PenetraMax showed a more rapid onset of absorption enhancement effects compared with those of D-penetratin. However, synergistic absorption enhancement effects after combination treatment were not observed. Next, we tried a theoretical approach to establish optimized oral insulin delivery conditions. A surface plasmon resonance (SPR)-based analysis demonstrated that binding between insulin and penetratin (2 mM) might be saturated at 100-500 µM penetratin, while the bound concentration of penetratin could increase in accordance with an increased concentration of mixed insulin. To test this hypothesis, we investigated the effectiveness of different insulin doses in the gastric pH-neutralized mice. The results showed that the dissociation of noncovalent complexes of insulin and CPPs at the low gastric pH was prevented in these mice. Our findings clearly suggested that a noncovalent strategy with CPPs represents an effective approach for the L-form of CPP to increase the concentration of CPP-bound insulin to attain greater absorption of insulin, although this approach may not be appropriate for the D-form of CPP. Our findings will contribute to the development of oral dosage forms of insulin for noncovalent strategies involving CPP.


Subject(s)
Cell-Penetrating Peptides/administration & dosage , Drug Delivery Systems , Hypoglycemic Agents/administration & dosage , Insulin, Regular, Human/administration & dosage , Intestinal Absorption/drug effects , Administration, Oral , Animals , Animals, Outbred Strains , Biological Availability , Carrier Proteins/administration & dosage , Carrier Proteins/chemistry , Carrier Proteins/pharmacokinetics , Carrier Proteins/pharmacology , Cell-Penetrating Peptides/chemistry , Cell-Penetrating Peptides/pharmacokinetics , Cell-Penetrating Peptides/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Famotidine/pharmacology , Gastric Acid/chemistry , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Histamine H2 Antagonists/pharmacology , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/pharmacology , Insulin, Regular, Human/genetics , Insulin, Regular, Human/pharmacokinetics , Insulin, Regular, Human/pharmacology , Ligands , Male , Mice , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacokinetics , Recombinant Proteins/pharmacology , Stereoisomerism , Surface Plasmon Resonance
SELECTION OF CITATIONS
SEARCH DETAIL
...